Regularly updated biosimilars material, in addition to our annual outputs. Includes specific information on ranibizumab for ocular use.

Understand the area

Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions

Resources to specifically support the introduction of ranibizumab biosimilar for ocular use.

Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance.
A licensed ranibizumab biosimilar is available from Teva: Ongavia. Learn about the licensed indications and supporting evidence.

All our resources on biosimilar medicines

Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance.
A licensed ranibizumab biosimilar is available from Teva: Ongavia. Learn about the licensed indications and supporting evidence.
Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
16 March 2022. An MUS Webinar with a discussion between specialist pharmacists
To support organisations in establishing a robust risk assessment process for new homecare medicines services the NHMC has developed a tool for local use.  …
NHMC submitted a proposal for the funding of Trust Pharmacy Homecare Teams to NHS England and NHS Clinical Commissioning for consideration. The NHMC hopes that…
These Good Practice Principles set out the National Homecare Medicines Committee’s (NHMC) expectations of Manufacturers offering Manufacturer Funded Homecare Medicine Services in relation to the…